Novartis and Gilead to launch CAR-T cell therapies in Denmark next year
Global drug group Novartis hopes to treat the first Danish cancer patient with the company's CAR-T cell therapy already by new years, while Gilead aims to be ready "during 2019". However, both companies must first get past the Danish Medicines Council.
Only two companies in the world have received permission to market the cancericide CAR-T cell therapies, and both are planning to bring their therapies to Denmark next year.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
